Surgery Partners Q3 2022 Earnings Report
Key Takeaways
Surgery Partners reported an 11.0% increase in revenue to $620.6 million, with same-facility revenues increasing 5.1%. Net loss attributable to common stockholders was $25.0 million, while Adjusted EBITDA reached $96.2 million, a nearly 26% increase from the prior year period. The company reaffirmed its projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.
Revenue increased 11.0% year-over-year to $620.6 million, with same-facility revenues up 5.1%.
Net loss attributable to common stockholders was $25.0 million, with Adjusted EBITDA of $96.2 million, nearly 26% greater than the prior year period.
Adjusted EBITDA margins increased sequentially and from the prior year period to 15.5% in the quarter.
The company reaffirmed its projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.
Surgery Partners
Surgery Partners
Surgery Partners Revenue by Segment
Forward Guidance
The Company reaffirms projected 2022 Adjusted EBITDA of $375 million to $385 million and anticipates revenue in the range of $2.5 billion to $2.55 billion.
Revenue & Expenses
Visualization of income flow from segment revenue to net income